The life science sector is a global field, with companies from the United States to China making significant advancements. These efforts in health and biology have attracted large investments, leading to high private company valuations.
The field includes companies like Biosplice Therapeutics, which is valued at $12 billion for its work in tissue regeneration. Another company, Kriya Therapeutics, has raised $921.3 million for its gene therapy developments.
Below is the full list of 20 Life Science unicorn startups at this time.
Top 10 Most Valuable Life Science Unicorns
Tool
Fundraising OS
Everything you need to raise funding for your startup, including 3,500+ investors, 7 tools, 18 templates and 3 learning resources.
Buy It For $97 $297 →Sheet
2,189 Accelerators & Incubators
Information about the industries, countries, and cities they generally invest in.
Get the Sheet for $50Sheet
1,600+ Unicorns
Information about their valuation, HQ's location, founded year, name of founders, funding amount and number of employees.
Get the Sheet for $50Sheet
250 BioTech & Health Investors
List of startup investors in the BioTech, Health, and Medicine industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50Sheet
250 AI Investors
List of 250 startup investors in the AI and Machine Learning industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50Sheet
250 Fintech Investors
List of 250 startup investors in the FinTech and Finance industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50Biosplice Therapeutics is creating first-in-class therapeutics by pioneering the science of alternative pre-mRNA splicing. Their clinical-stage programs aim to regenerate tissue and treat conditions like osteoarthritis and cancer.
| Valuation | $12B |
| Headquarters | San Diego, California, United States |
| Year Founded | 2008 |
| Founders | Osman Kibar |
| Funding Amount | $778M |
| Company Size | Mid-Size Team (51-250) |
| Last Funding Status | Venture Round |
| Top Investors | Vickers Venture Partners, aMoon Fund, Verition Fund Management, Sands Capital Ventures, Swicorp |
Colossal Biosciences uses breakthrough gene editing technology to bring back extinct species. Their work focuses on ambitious de-extinction projects, most notably the effort to resurrect the woolly mammoth.
| Valuation | $10B |
| Headquarters | Austin, Texas, United States |
| Year Founded | 2021 |
| Founders | Andrew Busey, Ben Lamm, Brian Beard, George Church, Kent Wakeford, Peter Phillips |
| Funding Amount | $568.1M |
| Company Size | Mid-Size Team (51-250) |
| Last Funding Status | Series C |
| Top Investors | Liquid 2 Ventures, Builders VC, Capital Factory, Draper Associates, US Innovative Technology Fund |
Benchling builds a cloud platform designed to modernize R&D for the life sciences industry. Their software helps scientific teams collaborate and accelerate their research from discovery through to manufacturing.
| Valuation | $6.1B (Joined April 2021) |
| Headquarters | San Francisco, California, United States |
| Year Founded | 2012 |
| Founders | Ashutosh Singhal, Cory Li, Sam Wickramasekara |
| Funding Amount | $411.9M |
| Company Size | Large Team (251-1,000) |
| Last Funding Status | Series F |
| Top Investors | Andreessen Horowitz, Franklin Templeton, Benchmark, Lux Capital, Menlo Ventures |
Sinovac Life Sciences researches, develops, and manufactures human vaccines. As a research-based company, they manage the entire product lifecycle from initial studies through to manufacturing and sales.
| Valuation | $3B |
| Headquarters | Beijing, Beijing, China |
| Year Founded | 2009 |
| Founders | Weidong Yin |
| Funding Amount | $500M |
| Company Size | No Data |
| Last Funding Status | Corporate Round |
| Top Investors | Sino Biopharmaceutical |
Insitro combines machine learning with high-throughput biology to create a new approach for drug discovery. Their platform generates predictive models of disease to help make the development of new therapeutics more efficient and successful.
| Valuation | $2.44B (Joined March 2021) |
| Headquarters | South San Francisco, California, United States |
| Year Founded | 2018 |
| Founders | Daphne Koller |
| Funding Amount | $643M |
| Company Size | Large Team (251-1,000) |
| Last Funding Status | Series C |
| Top Investors | Verily, Temasek Holdings, ARCH Venture Partners, BlackRock, Andreessen Horowitz |
Tessera Therapeutics pioneers a new category of genetic medicine with its Gene Writing™ technology. This platform is designed to cure diseases by writing therapeutic messages directly into the genome.
| Valuation | $2B (Joined April 2022) |
| Headquarters | Cambridge, Massachusetts, United States |
| Year Founded | 2018 |
| Founders | Geoffrey von Maltzahn, Jacob Rubens, Noubar Afeyan |
| Funding Amount | $623.1M |
| Company Size | Large Team (251-1,000) |
| Last Funding Status | Venture Round |
| Top Investors | Flagship Pioneering, Abu Dhabi Investment Authority, Bill & Melinda Gates Foundation, Artis Ventures, Cormorant Asset Management |
Kriya Therapeutics develops gene therapies for diseases in ophthalmology, neurology, and metabolic health. The company uses its fully integrated platform to design, manufacture, and analyze these advanced treatments.
| Valuation | $2B |
| Headquarters | Palo Alto, California, United States |
| Year Founded | 2019 |
| Founders | Fraser Wright, Roger Jeffs, Shankar Ramaswamy |
| Funding Amount | $921.3M |
| Company Size | Mid-Size Team (51-250) |
| Last Funding Status | Series D |
| Top Investors | Alumni Ventures, Amplo, Foresite Capital, Patient Square Capital, Narya Capital |
Pathos applies artificial intelligence to the complex process of oncology drug development, significantly speeding up the discovery of new treatments. Their platform analyzes biological data at a massive scale to uncover new pathways for fighting cancer.
| Valuation | $2B (Joined May 2025) |
| Headquarters | Chicago, Illinois, United States |
| Year Founded | 2020 |
| Founders | Eric Lefkofsky, Ryan Fukushima |
| Funding Amount | $447M |
| Company Size | Lean Team (11-50) |
| Last Funding Status | Series D |
| Top Investors | New Enterprise Associates, Lightbank, Revolution Growth, Builders VC |
Meril Life creates a diverse portfolio of medical devices, handling everything from design and manufacturing to global distribution. Their devices support a range of medical specialties and are developed to enhance the quality of patient care worldwide.
| Valuation | $2B |
| Headquarters | Vapi, Daman and Diu, India |
| Year Founded | 2006 |
| Founders | Dhruvi Kotadiya |
| Funding Amount | ₹15B |
| Company Size | Enterprise Organization (5,001+) |
| Last Funding Status | Private Equity |
| Top Investors | Warburg Pincus |
NantOmics created a molecular profiling service, GPS Cancer, that gives oncologists a detailed report of a patient's tumor. This analysis of the tumor's unique genomic and proteomic data helps guide personalized treatment plans for cancer patients.
| Valuation | $2B |
| Headquarters | Culver City, California, United States |
| Year Founded | 2012 |
| Founders | Patrick Soon-Shiong |
| Funding Amount | $250.8M |
| Company Size | Lean Team (11-50) |
| Last Funding Status | Series A |
| Top Investors | NantHealth |
The Remaining 10 Life Science Unicorns
The ten most valuable companies represent only a part of the growth happening in life sciences. Other startups are also reaching billion-dollar valuations and pushing the industry forward.
These next ten companies have collectively raised over $8 billion, with teams based in the United States, China, Japan, and India. Here’s a look at the other unicorn startups shaping the field.
